Chapter 1: Executive Summary
- Scope and Methodology
- Trends Affecting the Market
- The Urgent Need for Antivirals
- The Forecast for Vaccines, 1996‑2020
- The Impact of Managed Care on Drug Manufacturers
- Diversification
- Licensing Arrangements
- Mergers
- Pharmacy Benefit Plans
- Probationary Alliances
- Vertical Integration
- Virtual Integration
- Industry Structure and Leading Competitors
- New Arrangements to Meet New Challenges
- Consolidated Alliances
- The InterCompany Collaboration for AIDS Drug Development
- Changes Among Leading Antiviral Competitors
- The U.S. Market
- Notes on the Data
- Size of the Market
Chapter 2: Introduction to Viral Diseases
- Scope and Methodology
- Overview of Selected Viral Diseases
- AIDS and HIV Infection
- The Discovery of HIV
- Description of HIV
- Pathology
- Epidemiology
- Transmission
- Characteristics of Infected Populations
- Signs and Symptoms
- Worldwide Statistics
- United States Statistics
- The Expanded Definition of AIDS
- Survival Statistics
- Cost of Treating HIV Infection and AIDS [4]
- Dengue Fever
- Genital Warts
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Hepatitis G
- Hepatitis X
- Newly Discovered Strains of Hepatitis
- Herpesviruses
- Cytomegalovirus
- Epstein‑Barr Syndrome
- Herpes Simplex I
- Herpes Simplex II
- Herpes Zoster
- Human B19 Parvovirus
- Influenza
- Measles, Mumps, and Rubella
- Poliomyelitis
- Respiratory Syncytial Virus
- Rare and Emerging Viral Disease Threats
- Ebola Virus
- Hantavirus
- Junin Virus
- Lassa Virus
- Machupo Virus
- Marburg Virus
- Oropouche Virus
- Rift Valley Fever
- Sabia Virus
- Is There (Another) Coming Plague?
Chapter 3: Currently Available Antiviral Products
- Introduction
- AIDS and HIV Therapeutics
- New Product Approvals of 1994 and 1995
- Epivir
- Cytovene
- Foscavir
- Hivid
- Interferons
- Intron A
- Roferon‑A
- Invirase
- Retrovir
- Videx
- Zerit
- Hepatitis Products
- Therapeutics
- Immune Globulins
- Intron A
- Vaccines
- Engerix‑B and Recombivax HB
- Havrix
- Herpesvirus Products
- Therapeutics
- Alferon N Injection
- Famvir
- Valtrex
- Zovirax
- Vaccines
- Influenza Products
- Therapeutics
- Amantadine Hydrochloride and Rimantadine Hydrochloride
- Flumadine
- Symmetrel
- Vaccines
- Measles-Mumps-Rubella Combination Vaccines
- Polio Vaccines
- Respiratory Syncytial Virus Products
- Rare Disease and Other Products
Chapter 4: Antiviral Products in Development
- Notes on the Data
- Leading Antiviral Technologies
- Gene Therapy
- Vaccines
- First-Generation or Traditional Vaccines
- Second-Generation Vaccines
- AIDS and HIV Products
- Antivirals
- Apoptosis Agents
- Description
- Development of Anti‑Apoptosis Agent CoQ10
- Combination Therapy with Existing Products
- Gene Therapy
- Adoptive Transfer
- Antisense
- Direct Killing
- The Gene Gun
- Ribozymes
- Nucleotide‑Based Drugs
- Protease Inhibitors
- Crixivan
- Palinavir
- Ritonavir
- Viracept
- VX‑478
- Other Protease Inhibitors in Development
- Reverse Transcriptase Inhibitors
- Vaccines
- Vaccine Development Strategies
- Live, Killed, and Genetically Engineered Viruses
- Genetically Engineered AIDS Vaccines
- Phases of AIDS Vaccine Trials
- AIDS Vaccines in Clinical Trials
- gp120 Vaccines
- gp160 Vaccines
- HIV‑Immunogen
- VaxSyn
- Other Vaccines
- CD26
- HGP‑30
- p24 Vaccine
- RP400c Vaccine
- Targets for Future AIDS Vaccine Design
- Cytomegalovirus Infection
- Dengue Fever
- Genital Warts
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Hepatitis X
- Herpesviruses
- Therapeutics
- New Indications for Famvir
- Trials Comparing Famvir and Valaciclovir in the Treatment of HSV Infections
- Other Herpesvirus Treatments in Development
- Vaccines
- Products in Development
- Survey of Acceptance of a Genital Herpes Vaccine
- Human B19 Parvovirus
- Influenza
- Respiratory Syncytial Virus
- Rare Disease and Other Products
Chapter 5: Issues and Trends
- Market Trends
- The Urgent Need for Antivirals
- Prophylactic Vaccines
- Government Support of Antiviral Research
- Patent Expirations
- Protease Inhibitors—Will High Production Costs Force High Prices?
- The Forecast for Vaccines, 1996‑2020
- Increasing Emphasis on Immunization Worldwide
- New Vaccine Products Expand the Market
- Trends in the European Antiviral Vaccines Market
- Cost versus Efficiency of the Varicella Vaccine
- Industry Trends
- The Impact of Managed Care on Drug Manufacturers
- Pricing
- Diversification
- Licensing Arrangements
- Mergers
- Pharmacy Benefit Plans
- Probationary Alliances
- Vertical Integration
- Virtual Integration
- Patent Disputes
- Consolidated Alliances
- The InterCompany Collaboration for AIDS Drug Development
- Strategies for Successfully Developing Gene Therapy Products
- The Multi‑Vector Approach
- Genomics
- Investors Bullish on Genomics
- The Gene Club
- Overseas Launch
- Barriers to Entry in the Vaccine Market
- Regulatory Trends
- Factors Affecting New Anti‑AIDS Drug Development
- The United States Food and Drug Administration
- New FDA Initiatives to Expedite Approval of Promising Drugs
- Expedited Review for Drugs to Treat Life‑threatening Diseases
- Treatment-Use Applications
- Parallel Track Policy
- Emergency or Compassionate Use Protocols
- Patent Protection for Gene Therapy
- Technology Trends
- Development of an AIDS Vaccine—A Road Fraught With Adversity
- Vaccines Against Viral Strains of HIV That No Longer Exist
- Preventive or Therapeutic Treatment
- Novel Delivery Systems
- Liposomes
- Microspheres
- Nanoparticles
- Leading Competitors in the Antivirals Market—Today and Tomorrow
Chapter 6: The U.S. Market
- Scope and Methodology
- Notes on the Data
- Antiviral Therapeutics and Vaccines
- AIDS and HIV Therapeutics
- Size of the Market
- Usage Trends
- Hepatitis Products
- Therapeutics
- Size of the Market
- Market Composition
- Vaccines
- Size of the Market
- Usage Trends
- Herpesvirus Products
- Therapeutics
- Size of the Market
- Usage Trends
- Vaccines
- Size of the Market
- Influenza Products
- Therapeutics
- Size of the Market
- Vaccines
- Size of the Market
- Usage Trends
- Measles-Mumps-Rubella Combination Vaccines
- Oral Polio Vaccines
- Respiratory Syncytial Virus Therapeutics
- Rare Disease and Other Products
Chapter 7: Corporate Profiles
- Amgen, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Biogen, Inc.
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Bristol‑Myers Squibb Company
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- E.I. Du Pont de Nemours
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Genelabs Technologies, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Genentech, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Gilead Sciences, Inc.
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Glaxo Wellcome Company
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- ICN Pharmaceuticals, Inc.
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Interferon Sciences, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Isis Pharmaceuticals, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- MedImmune, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Merck & Company, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- MicroProbe Corporation
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Protein Design Labs, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Roche Holding Limited
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Shaman Pharmaceuticals
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- SmithKline Beecham Plc
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- The Upjohn Company
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Verex Laboratories, Inc
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Viragen, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Warner Chilcott Laboratories
- History and Lines of Business
- Financial Information
- Products
- Corporate Strategies
- Wyeth‑Ayerst Laboratories
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
Appendix A: Commonly Used Antiviral Products
Appendix B: Company Names and Addresses
More United States Vaccines Reports
Vaccines in the US by
Taiyou Research
The market for vaccines in the US is all set to experience a major growth in the coming times. The ever rising demand for vaccines ...
Retail Clinics 2011: Growth of Stores, Best Venues, Winning Competitors, Supplier Sales of Products to Clinics, Clinic Sales Forecasts and Trends by
Kalorama Information
Convenience clinics, also known as retail health clinics, are a quickly growing segment of the U.S. health care marketplace, although their expansion has slowed somewhat ...
Freedonia Focus on Biologicals by
Freedonia Focus
This report discusses US biologicals demand for the years 2004 and 2009, with forecasts for 2014. Topics covered include market size, product and ...
Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines by
Datamonitor
Introduction Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that could reach $3.4 billion in infants and ...
Freedonia Focus on Vaccines by
Freedonia Focus
This report discusses US vaccines for the years 2004 and 2009, with forecasts for 2014. Topics covered include market size, product segmentation, trade, vaccine ...
See all reports like this >>
More United States Reports
e-Discovery Software Publishing in the US - Industry Market Research Report by
IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...
D&B Country RiskLine Report: The United States of America by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by
Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>
